Wyeth received the US Food and Drug Administration(FDA) approval for Desvenlafaxine succinate (Pristiq™ ) a novel, once-daily serotonin-norepinephrine reuptake inhibitor (SNRI),for  the treatment of adult patients with major depressive disorder (MDD).